Epstein Barr virus (EBV) - Epidemiology Forecast - 2036

Epstein-Barr Virus (EBV) Insights and Trends

• Epstein-Barr Virus (EBV) is also known to cause infectious mononucleosis, a self-limited flu-like illness, in adolescents. EBV is often reactivated, and it employs several mechanisms of evading the host immune system. It has also been implicated in inducing host immune dysfunction, potentially resulting in exacerbation or triggering of inflammatory processes.
• EBV has therefore been linked to several autoimmune diseases, including systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, and Sjogren's syndrome.
• Most people worldwide are infected with the EBV at some point in their lives. It generally causes mild or no symptoms, so many individuals remain unaware of the infection. However, in some cases, it can lead to a more serious condition known as infectious mononucleosis, commonly referred to as "mono" or the "kissing disease."
• EBV infects around 90% of adults worldwide, with primary infection usually occurring in childhood.
• The age of infection varies by geography, race/ethnicity, and socioeconomic factors, which are important considerations for developing effective EBV vaccination programs.
• According to the Centers for Disease Control and Prevention (CDC), about 9 out of 10 people have been infected with EBV. It is a type of herpes virus that spreads easily through saliva (spit) and other bodily fluids. Most people get EBV as children.

DelveInsight's 'Epstein-Barr Virus (EBV) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the EBV, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Epstein-Barr Virus (EBV) Understanding and Diagnosis Algorithm

Epstein-Barr Virus (EBV) Overview and Diagnosis

Epstein-Barr virus (EBV) is a highly prevalent herpesvirus that infects nearly 90% of the global adult population. It is primarily transmitted through saliva and often causes asymptomatic or mild infection, especially in childhood. In adolescents and adults, EBV can lead to infectious mononucleosis ("mono"). The virus establishes lifelong latency in the body and can reactivate under certain conditions. EBV is also associated with several malignancies and lymphoproliferative disorders, particularly in immunocompromised individuals.

Epstein-Barr Virus (EBV) Diagnosis

Diagnosis of EBV is based on a combination of clinical presentation and laboratory testing. Common tests include heterophile antibody tests (Monospot) for rapid screening and EBV-specific serology (e.g., VCA-IgM, VCA-IgG, EBNA) to determine the stage of infection. In certain cases, especially in immunocompromised patients, PCR-based assays are used to detect and quantify EBV DNA. Additional findings, such as atypical lymphocytosis and elevated liver enzymes, may support the diagnosis.

Epstein-Barr Virus (EBV) Epidemiology

Key Findings from Epstein-Barr Virus (EBV) Epidemiological Analysis and Forecast

• According to secondary analysis, the overall seroprevalence of EBV for children aged 6-19 in the United States was 66.5%. This ranged from 54.1% among 6-8-year-olds to 82.9% among 18-19-year-olds. Males were slightly less likely to be infected than females (64.2% vs. 68.9%).
• EBV infects up to 95% of adults globally. The prevalence of EBV varies by type of EBV and geographic region. EBV type 1 is the most common and is found worldwide, with a higher prevalence in Europe, Asia, North America, and South America.
• EBV resides silently in 19 out of 20 Americans and can cause a small group of immune cells to become abnormal, triggering a widespread immune response against the body's tissues.
• As per studies, more than 99% of patients with multiple sclerosis have been infected with EBV, which is notably higher than the 90-95% seroprevalence observed in the general population. With improved assay sensitivity and stricter diagnostic criteria, EBV seropositivity in individuals with multiple sclerosis is considered to be nearly 100%.
• As per studies, in lupus patients, the fraction of EBV-infected B cells rises to about 1 in 400 - a 25-fold difference.
• In a comprehensive study, it is reported that EBV infection is a pivotal contributor to multiple sclerosis. The research analyzed data from a large cohort of over 10 million young adults in the US military, among whom 955 individuals were diagnosed with sclerosis during their active duty.
• According to secondary analysis. The study evaluated individuals with rheumatoid arthritis undergoing treatment, comparing clinical and laboratory characteristics based on anti-EBV EA-DR IgG antibody status. A notable proportion (43.9%) tested positive, indicating a significant presence of EBV-related antibodies within this population.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of Epstein-Barr Virus (EBV), explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Epstein-Barr Virus (EBV) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Epstein-Barr Virus (EBV)? What will be the growth opportunities across the 7MM concerning the patient population with Epstein-Barr Virus (EBV)?
• What is the historical and forecasted Epstein-Barr Virus (EBV) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence/incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.